REVERSIBLE BILATERAL SUBFOVEAL ELLIPSOID ZONE FOCAL THICKENING ASSOCIATED WITH OVERDOSE OF PHOSPHODIESTERASE TYPE 5...

To describe the clinical findings and outcome of an unusual case of subfoveal yellowish deposits associated with excessive doses of phosphodiesterase Type 5 inhibitors intake.

Single retrospective case report.

A 50-year-old South American man with a personal history of multiple orally administered phosphodiesterase Type 5 inhibitors drugs to treat a chronic erectile dysfunction complained of dyschromatopsia, photophobia, and a 3-month history of blurred vision. The fundus examination revealed a symmetrical yellowish lesion in both eyes with a subfoveal hyperreflective signal on the spectral domain optical coherence tomography at the level of the ellipsoid zone. Dysregulation of the blue-yellow axis was noticed in the color vision test and the electroretinogram demonstrated a tiny decrease in the b-wave amplitude. The use of phosphodiesterase Type 5 inhibitors was discontinued and the patient was examined 3 months later. Optical coherence tomography revealed complete disappearance of the deposit in both eyes and the associated symptoms resolved rapidly with discontinuation of the drug.

A bilateral ellipsoid zone subfoveal focal thickening may be related to a yellowish symmetrical spot on the fovea in patients with a history of phosphodiesterase Type 5 inhibitors overdose intake. Functional and structural findings are reversible in a short-term period after discontinuing the oral treatment.